Demographics and clinical characteristics of patients subjected to genomic profiling
| . | CML . | AP/BP . | CP . | |||||
|---|---|---|---|---|---|---|---|---|
| CP-All . | Progressive . | Poor . | Response . | |||||
| All . | Suboptimal . | Optimal . | ||||||
| Patients, n | 59 | 16 | 43* | 3 | 4 | 33 | 13 | 20 |
| Age, median (range), y | 50 (24-78) | 47.89 (24-74) | 51.18 (27-78) | 41 (35-46) | 45 (27-54) | 51 (29-78) | 50 (29-67) | 59 (29-78) |
| Sex, male:female, n (%) | 32:23 (58:42) | 10:6 (63:37) | 21:15 (60:40) | 1:2 (33:67) | 3:1 (75:25) | 17:14 (52:48) | 7:6 (54:46) | 10:8 (56:44) |
| Disease stage at diagnosis, CP/AP/BP, n (%) | 51/3/5 (86:5:9) | 8/3/5 (50/19/31) | 43/0/0 (100/0/0) | 3/0/0 (100/0/0) | 4/0/0 (100/0/0) | 33/0/0 (100/0/0) | 13/0/0 (100/0/0) | 20/0/0 (100/0/0) |
| Hb at diagnosis, median (range), g/L | 118 (78-157) | 119 (78-157) | 117.5 (78-156) | 130 (85-144) | 93 (93-95) | 120.5 (78-156) | 105 (78-143) | 122 (91-156) |
| WBC count at diagnosis, median (range), ×109/L | 59 (3.78-365) | 55.5 (3.78-317) | 67 (14-365) | 21.6 (16.9-174.1) | 319 (238-345) | 46 (14-365) | 75 (28-327) | 44 (14-365) |
| Platelet count at diagnosis, median (range), ×109/L | 457 (19-2674) | 210.5 (19-1048) | 480 (120-2674) | 860 (156-2570) | 565 (393-584) | 480 (120-2674) | 325 (120-620) | 655 (127-2674) |
| PB blast at diagnosis, n (%) | 1 (0-46) | 10 (4-46) | 0.5 (0-6) | 0 (0-6) | 2 (2-3) | 0 (0-6) | 0 (0-6) | 0 (0-4) |
| BM blast at diagnosis, n (%) | 3 (0-90) | 45 (6-90) | 3 (0-8) | 2 (2-3) | 3 (2-4) | 3 (0-8) | 2 (0-6) | 3 (0-8) |
| Spleen size at diagnosis, median (range), cm | 13.5 (0-30) | 15 (0-30) | 13 (0-30) | 12 (0-15) | 25 (12-30) | 12 (0-23) | 13.75 (0-23) | 9 (0-21) |
| Sokal score, low/intermediate/high/NA, median (range) | 12/10/11/26 | 0/0/0/16 | 0.89 (0.51-3.45) 12/10/11/7 | 1.18 (0.56-7.4) 1/1/1/0 | 1.02 (0.73-1.89) 1/1/1/0 | 0.89 (0.51-3.45) 10/8/9/6 | 0.82 (0.52-1.76) 5/3/2/3 | 0.9 (0.51-3.45) 5/5/7/3 |
| Hasford score, low/intermediate/high/NA, median (range) | 11/13/8/27 | 0/0/0/16 | 891 (100-2384) 11/13/8/8 | 720 (328-1299) 1/2/0/0 | 908 (199-2176) 1/1/1/0 | 873 (100-2384) 9/11/5/8 | 866 (124-1306) 4/5/0/4 | 1106 (100-2384) 5/6/5/4 |
| Additional cytogenetic abnormalities at diagnosis, n/N (%) | 13/56 (23.2) | 10/16 (62.5) | 3/40 (7.5) | 0/3 (0) | 1/4 (25) | 2/33 (6) | 0/13 (0) | 2/20 (10) |
| Frontline treatment, imatinib/2G TKI/Chemotherapy/NA, n | 34/21/3/1 | 10/3/3/0 | 21/18/0/1 | 3/0/0/0 | 2/2/0/0 | 18/15/0/0 | 8/5/0/0 | 10/10/0/0 |
| Clinical responses poor/suboptimal/optimal/NA, n | 4/13/20/22 | 0/0/0/16 | 4/13/20/3 | 3/0/0/0 | 4/0/0/0 | 0/13/20/0 | 0/13/0/0 | 0/0/20/0 |
| Interval between diagnosis and follow-up samples, median (range), mo | — | — | 6 (3-30) | — | 3 (3) | 6 (3-30) | 6 (3-30) | 4.5 (3-19) |
| Response at follow-up sampling time, minCyR/PCyR/CCyR/MMR, n | — | — | 3/2/15/5 | — | 2/0/0/0 | 1/2/15/5 | 1/1/9/0 | 0/1/6/5 |
| Time to achieve MMR, median (range) (at 12 mo/after 12 mo/never), mo | — | — | 12 (3-70) 18/14/4/4 | — | 0/0/4/0 | 12 (3-70) 18/14/0/0 | 30 (15-70) 0/14/0/0 | 6 (3-12) 18/0/0/0 |
| . | CML . | AP/BP . | CP . | |||||
|---|---|---|---|---|---|---|---|---|
| CP-All . | Progressive . | Poor . | Response . | |||||
| All . | Suboptimal . | Optimal . | ||||||
| Patients, n | 59 | 16 | 43* | 3 | 4 | 33 | 13 | 20 |
| Age, median (range), y | 50 (24-78) | 47.89 (24-74) | 51.18 (27-78) | 41 (35-46) | 45 (27-54) | 51 (29-78) | 50 (29-67) | 59 (29-78) |
| Sex, male:female, n (%) | 32:23 (58:42) | 10:6 (63:37) | 21:15 (60:40) | 1:2 (33:67) | 3:1 (75:25) | 17:14 (52:48) | 7:6 (54:46) | 10:8 (56:44) |
| Disease stage at diagnosis, CP/AP/BP, n (%) | 51/3/5 (86:5:9) | 8/3/5 (50/19/31) | 43/0/0 (100/0/0) | 3/0/0 (100/0/0) | 4/0/0 (100/0/0) | 33/0/0 (100/0/0) | 13/0/0 (100/0/0) | 20/0/0 (100/0/0) |
| Hb at diagnosis, median (range), g/L | 118 (78-157) | 119 (78-157) | 117.5 (78-156) | 130 (85-144) | 93 (93-95) | 120.5 (78-156) | 105 (78-143) | 122 (91-156) |
| WBC count at diagnosis, median (range), ×109/L | 59 (3.78-365) | 55.5 (3.78-317) | 67 (14-365) | 21.6 (16.9-174.1) | 319 (238-345) | 46 (14-365) | 75 (28-327) | 44 (14-365) |
| Platelet count at diagnosis, median (range), ×109/L | 457 (19-2674) | 210.5 (19-1048) | 480 (120-2674) | 860 (156-2570) | 565 (393-584) | 480 (120-2674) | 325 (120-620) | 655 (127-2674) |
| PB blast at diagnosis, n (%) | 1 (0-46) | 10 (4-46) | 0.5 (0-6) | 0 (0-6) | 2 (2-3) | 0 (0-6) | 0 (0-6) | 0 (0-4) |
| BM blast at diagnosis, n (%) | 3 (0-90) | 45 (6-90) | 3 (0-8) | 2 (2-3) | 3 (2-4) | 3 (0-8) | 2 (0-6) | 3 (0-8) |
| Spleen size at diagnosis, median (range), cm | 13.5 (0-30) | 15 (0-30) | 13 (0-30) | 12 (0-15) | 25 (12-30) | 12 (0-23) | 13.75 (0-23) | 9 (0-21) |
| Sokal score, low/intermediate/high/NA, median (range) | 12/10/11/26 | 0/0/0/16 | 0.89 (0.51-3.45) 12/10/11/7 | 1.18 (0.56-7.4) 1/1/1/0 | 1.02 (0.73-1.89) 1/1/1/0 | 0.89 (0.51-3.45) 10/8/9/6 | 0.82 (0.52-1.76) 5/3/2/3 | 0.9 (0.51-3.45) 5/5/7/3 |
| Hasford score, low/intermediate/high/NA, median (range) | 11/13/8/27 | 0/0/0/16 | 891 (100-2384) 11/13/8/8 | 720 (328-1299) 1/2/0/0 | 908 (199-2176) 1/1/1/0 | 873 (100-2384) 9/11/5/8 | 866 (124-1306) 4/5/0/4 | 1106 (100-2384) 5/6/5/4 |
| Additional cytogenetic abnormalities at diagnosis, n/N (%) | 13/56 (23.2) | 10/16 (62.5) | 3/40 (7.5) | 0/3 (0) | 1/4 (25) | 2/33 (6) | 0/13 (0) | 2/20 (10) |
| Frontline treatment, imatinib/2G TKI/Chemotherapy/NA, n | 34/21/3/1 | 10/3/3/0 | 21/18/0/1 | 3/0/0/0 | 2/2/0/0 | 18/15/0/0 | 8/5/0/0 | 10/10/0/0 |
| Clinical responses poor/suboptimal/optimal/NA, n | 4/13/20/22 | 0/0/0/16 | 4/13/20/3 | 3/0/0/0 | 4/0/0/0 | 0/13/20/0 | 0/13/0/0 | 0/0/20/0 |
| Interval between diagnosis and follow-up samples, median (range), mo | — | — | 6 (3-30) | — | 3 (3) | 6 (3-30) | 6 (3-30) | 4.5 (3-19) |
| Response at follow-up sampling time, minCyR/PCyR/CCyR/MMR, n | — | — | 3/2/15/5 | — | 2/0/0/0 | 1/2/15/5 | 1/1/9/0 | 0/1/6/5 |
| Time to achieve MMR, median (range) (at 12 mo/after 12 mo/never), mo | — | — | 12 (3-70) 18/14/4/4 | — | 0/0/4/0 | 12 (3-70) 18/14/0/0 | 30 (15-70) 0/14/0/0 | 6 (3-12) 18/0/0/0 |
CML, all patients in our cohort (n = 59); AP/BP, the blast phase subset (n = 16); CP/CP-All, chronic phase subset (n = 43). Fractionation of CP patients into subsets based on their treatment responses: progressive, patients progressed to AP/BP; poor, patients who failed to achieve MMR at any time; responsive, patients who achieved MMR either by 12 months (optimal) or after 12 months (suboptimal).
2G, second generation; BM, bone marrow; CCyR, complete cytogenetic response; Hb, hemoglobin; MMR, major molecular response; minCyR, minimal cytogenetic response; NA: no available data; PB, peripheral blood; PCyR, partial cytogenetic response; WBC, white blood cell.
Clinical data were missing for 3 CP patients.